Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR) by Ward, Richard A, Anderton, Mark J, Ashton, Susan, Bethel, Paul A, Box, Matthew, Butterworth, Sam, Colclough, Nicola, Chorley, Christopher G, Chuaqui, Claudio, Cross, Darren A. E, Dakin, Les A, Debreczeni, Judit É, Eberlein, Cath, Finlay, M. Raymond V, Hill, George B, Grist, Matthew, Klinowska, Teresa C. M, Lane, Clare, Martin, Scott, Orme, Jonathon P, Smith, Peter, Wang, Fengjiang, Waring, Michael J

Get full text

Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation by Hennessy, Edward J, Chuaqui, Claudio, Ashton, Susan, Colclough, Nicola, Cross, Darren A. E, Debreczeni, Judit É, Eberlein, Cath, Gingipalli, Lakshmaiah, Klinowska, Teresa C. M, Orme, Jonathan P, Sha, Li, Wu, Xiaoyun

Get full text

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists by Scott, James S., Stead, Darren, Barlaam, Bernard, Breed, Jason, Carbajo, Rodrigo J., Chiarparin, Elisabetta, Cureton, Natalie, Davey, Paul R. J., Fisher, David I., Gangl, Eric T., Grebe, Tyler, Greenwood, Ryan D., Hande, Sudhir, Hatoum-Mokdad, Holia, Hughes, Samantha J., Hunt, Thomas A., Johnson, Tony, Kavanagh, Stefan L., Klinowska, Teresa C. M., Larner, Carrie J. B., Lawson, Mandy, Lister, Andrew S., Longmire, David, Marden, Stacey, McGuire, Thomas M., McMillan, Caroline, McMurray, Lindsay, Morrow, Christopher J., Nissink, J. Willem M., Moss, Thomas A., O’Donovan, Daniel H., Polanski, Radoslaw, Stokes, Stephen, Thakur, Kumar, Trueman, Dawn, Truman, Caroline, Tucker, Michael J., Wang, Haixia, Whalley, Nicky, Wu, Dedong, Wu, Ye, Yang, Bin, Yang, Wenzhan

Get full text

Cell–matrix interactions during development and apoptosis of the mouse mammary gland in vivo by Prince, Janine M., Klinowska, Teresa C.M., Marshman, Emma, Lowe, Emma T., Mayer, Ulrike, Miner, Jeff, Aberdam, Daniel, Vestweber, Dietmar, Gusterson, Barry, Streuli, Charles H.

Get full text

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER + /HER2 - Advanced Breast Cancer by Hamilton, Erika P, Patel, Manish R, Armstrong, Anne C, Baird, Richard D, Jhaveri, Komal, Hoch, Matthias, Klinowska, Teresa, Lindemann, Justin P O, Morgan, Shethah R, Schiavon, Gaia, Weir, Hazel M, Im, Seock-Ah

Get full text

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules by Guichard, Sylvie M, Curwen, Jon, Bihani, Teeru, D'Cruz, Celina M, Yates, James W T, Grondine, Michael, Howard, Zoe, Davies, Barry R, Bigley, Graham, Klinowska, Teresa, Pike, Kurt G, Pass, Martin, Chresta, Christine M, Polanska, Urszula M, McEwen, Robert, Delpuech, Oona, Green, Stephen, Cosulich, Sabina C

Get full text

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection by Cani, Andi K., Dolce, Emily M., Darga, Elizabeth P., Hu, Kevin, Liu, Chia‐Jen, Pierce, Jackie, Bradbury, Kieran, Kilgour, Elaine, Aung, Kimberly, Schiavon, Gaia, Carroll, Danielle, Carr, T. Hedley, Klinowska, Teresa, Lindemann, Justin, Marshall, Gayle, Rowlands, Vicky, Harrington, Elizabeth A., Barrett, J. Carl, Sathiyayogan, Nitharsan, Morrow, Christopher, Sero, Valeria, Armstrong, Anne C., Baird, Richard, Hamilton, Erika, Im, Seock‐Ah, Jhaveri, Komal, Patel, Manish R., Dive, Caroline, Tomlins, Scott A., Udager, Aaron M., Hayes, Daniel F., Paoletti, Costanza

Get full text

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diag... by Robertson, John F R, Evans, Abigail, Henschen, Stephan, Kirwan, Cliona C, Jahan, Ali, Kenny, Laura M, Dixon, J Michael, Schmid, Peter, Kothari, Ashutosh, Mohamed, Omar, Fasching, Peter A, Cheung, Kwok-Leung, Wuerstlein, Rachel, Carroll, Danielle, Klinowska, Teresa, Lindemann, Justin P O, MacDonald, Alexander, Mather, Richard, Maudsley, Rhiannon, Moschetta, Michele, Nikolaou, Myria, Roudier, Martine P, Sarvotham, Tinnu, Schiavon, Gaia, Zhou, Diansong, Zhou, Li, Harbeck, Nadia

Get full text

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-a... by Fu, Xiaoyong, Creighton, Chad J, Biswal, Nrusingh C, Kumar, Vijetha, Shea, Martin, Herrera, Sabrina, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Nanda, Sarmistha, Giuliano, Mario, Morrison, Gladys, Nardone, Agostina, Karlin, Kristen L, Westbrook, Thomas F, Heiser, Laura M, Anur, Pavana, Spellman, Paul, Guichard, Sylvie M, Smith, Paul D, Davies, Barry R, Klinowska, Teresa, Lee, Adrian V, Mills, Gordon B, Rimawi, Mothaffar F, Hilsenbeck, Susan G, Gray, Joe W, Joshi, Amit, Osborne, C Kent, Schiff, Rachel

Get full text

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase by Ballard, Peter, Barlaam, Bernard C., Bradbury, Robert H., Dishington, Allan, Hennequin, Laurent F.A., Hickinson, D. Mark, Hollingsworth, Ian M., Kettle, Jason G., Klinowska, Teresa, Ogilvie, Donald J., Pearson, Stuart E., Scott, James S., Suleman, Abid, Whittaker, Robin, Williams, Emma J., Wood, Robin, Wright, Lindsay

Get full text

Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket by Ballard, Peter, Bradbury, Robert H., Harris, Craig S., Hennequin, Laurent F.A., Hickinson, Mark, Johnson, Paul D., Kettle, Jason G., Klinowska, Teresa, Leach, Andrew G., Morgentin, Remy, Pass, Martin, Ogilvie, Donald J., Olivier, Annie, Warin, Nicolas, Williams, Emma J.

Get full text